Company Focus
Merck KGaA
Latest Merck KGaA News
Pharmaceutical
German pharma and life sciences major Merck KGaA today announced that the UK National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending Ogsiveo (nirogacestat) for the treatment of adults with progressing desmoid tumors who require systemic treatment. 25 September 2026
Related News
Insights
Company Spotlight
A UK life science investor, listed in London and managed by a team the Wellcome Trust founded in 2012, that builds and funds biotech companies from British science and is now focused on returning at least £250 million ($336.8 million) to shareholders from a portfolio of 15 companies.
Latest News & Features of interest to Merck KGaA
Biotechnology
Antibody-drug conjugates (ADCs) bring together two familiar approaches to cancer treatment: an antibody that recognizes a target on a cell and a powerful drug that kills it. Connecting them offers a way to deliver chemotherapy more selectively, although it does not prevent the medicine from damaging healthy tissue. 12 October 2026
Pharmaceutical
US biotech company Revolution Medicines faces fresh questions about how its pancreatic cancer treatment Rasonque (daraxonrasib) performs across different KRAS mutations, following publication of regulatory review documents. 12 October 2026
Pharmaceutical
Belgian pharma trade group pharma.be welcomes the new Belgian Cancer Plan 2026-2036. The innovative biopharmaceutical sector has been advocating for a new cancer plan for years and is pleased that a framework is now in place to further strengthen the fight against cancer in Belgium. 12 October 2026
Pharmaceutical
US biopharma company Mineralys Therapeutics today announced the presentation of a new analysis from its pivotal Phase III Launch-HTN trial, showing that at Week 12, 46% of lorundrostat-treated participants achieved the AHA/ACC Guideline recommended office systolic blood pressure (SBP) target of <130 mmHg. 9 October 2026
Pharmaceutical
Israel-based Teva Pharmaceutical Industries US subsidiary today revealed that the US Food and Drug Administration (FDA) has approved Weltruza (olanzapine) for extended-release injectable suspension, a new, once-monthly, subcutaneous long-acting injectable (LAI) for the treatment of schizophrenia in adults. 9 October 2026
Biotechnology
Iambic Therapeutics, the San Diego-based AI drug discovery company, has set terms for a Nasdaq initial public offering of 9,375,000 shares priced at $15 to $17 each, under the proposed ticker IAM, according to an amended S-1 filed with the SEC Thursday. 9 October 2026
Pharmaceutical
When the World Health Organization (WHO) updates its Model List of Essential Medicines (EML), it gives governments a reference point for deciding which treatments their health systems should prioritize. Its choices can inform public purchasing and insurance coverage, although countries make their own decisions about what to fund. 9 October 2026
Biotechnology
Belgian life sciences company SpectaCell has launched with 6 million euros ($6.7 million) in seed financing to develop a cell analysis platform intended to help drugmakers assess immune therapies, from early research through manufacturing. 9 October 2026
Biotechnology
The US Food and Drug Administration (FDA) has approved oche’s Tecentriq atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer, a type of tumor characterized by high mutation rates. 9 October 2026
Pharmaceutical
US pharma major Bristol Myers Squibb said its Phase III EXCALIBER-RRMM trial met its progression-free survival (PFS) endpoint, with Zenbexus (iberdomide) plus daratumumab and dexamethasone (ZDd) beating daratumumab, bortezomib and dexamethasone (DVd) in relapsed or refractory multiple myeloma, including patients at first relapse. 8 October 2026
Latest In Brief for Merck KGaA
Pharmaceutical
Spanish drugmaker PharmaMar has announced that health authorities in Canada, Qatar and South Korea have approved Zepzelca (lurbinectedin) in combination with atezolizumab (Roche’s Tecentriq) for the maintenance treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed following first-line induction therapy with atezolizumab, carboplatin and etoposide. 25 August 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze